ArticleFrontiers in oncology2026
Chemotherapy management of a pediatric B-ALL patient with moyamoya disease: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Moyamoya disease is a rare, chronic cerebrovascular disorder characterized by progressive stenosis or occlusion of the terminal portions of the internal carotid arteries and the subsequent development of abnormal compensatory vascular networks. It represents a significant cause of intracranial arteriopathy and is a major etiology of stroke and transient ischemic attack in pediatric populations. We present the case of a 9-year-old boy with confirmed diagnosis of B-cell acute lymphoblastic leukemia (B-ALL), in whom brain MRI findings were suggestive of Moyamoya disease. This report underscores the rarity of the co-occurrence of B-ALL and Moyamoya disease and highlights the importance of early recognition and timely intervention during chemotherapy to reduce the risk of neurological complications. Our findings may offer valuable insights for the chemotherapeutic management of ALL patients with coexisting Moyamoya disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.